As of today (2026-06-25), the Trailing Annual Dividend Yield of Adaptive Biotechnologies is 0.00%.
The historical rank and industry rank for Adaptive Biotechnologies's Dividend Yield % or its related term are showing as below:
FRA:1HM's Dividend Yield % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.71 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1HM vs GRAL, WGS, NEO: Dividend Yield % Comparison
For the Diagnostics & Research subindustry, Adaptive Biotechnologies's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adaptive Biotechnologies Dividend Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Adaptive Biotechnologies's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Adaptive Biotechnologies's Dividend Yield % falls into.
Adaptive Biotechnologies (FRA:1HM) has a Dividend Yield % of 0.00% as of Jun. 25, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Adaptive Biotechnologies and its competitors. According to the industry distribution chart, Adaptive Biotechnologies ranks #999999 out of 65 companies in the Medical Diagnostics & Research industry.
Is Adaptive Biotechnologies' Dividend Yield % too high?
Adaptive Biotechnologies' current Dividend Yield % is 0.00%. Based on the distribution chart, Adaptive Biotechnologies ranks #999999 out of 65 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Adaptive Biotechnologies has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' Dividend Yield % compare to GRAL and WGS?
According to the Medical Diagnostics & Research industry distribution chart, Adaptive Biotechnologies ranks #999999 out of 65 companies for Dividend Yield %. This places Adaptive Biotechnologies in the lower half of its industry. The industry median Dividend Yield % is 1.71. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Medical Diagnostics & Research company?
The median Dividend Yield % among Medical Diagnostics & Research companies is 1.71, based on 65 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Adaptive Biotechnologies and its competitors. For the Medical Diagnostics & Research industry, the median Dividend Yield % is 1.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adaptive Biotechnologies's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (FRA:1HM) is currently considered Significantly Overvalued. The stock's GF Value™ is €8.07, compared to a current price of €15.50 — trading 92.1% above its estimated fair value. The current Dividend Yield % is 0.00%. Adaptive Biotechnologies' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Adaptive Biotechnologies (FRA:1HM), the current Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adaptive Biotechnologies (FRA:1HM) Overvalued in 2026?
Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued.
The current stock price of €15.50 is trading 92.1% above its estimated GF Value™ of €8.07.
GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.
Key valuation signals for FRA:1HM:
Dividend Yield %: 0.00%
GF Value™: €8.07 vs. price of €15.50 (92.1% above fair value)
No single metric tells the full story. See the FRA:1HM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
73GF Score
Get the complete analysis for FRA:1HM
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1HM has been successfully added to your 
